

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



TIAN YUAN HEALTHCARE

天 元 醫 療

**CHINA TIAN YUAN HEALTHCARE GROUP LIMITED**

**中國天元醫療集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 557)**

**(I) FURTHER DELAY IN PUBLICATION OF THE 2020 INTERIM  
RESULTS AND DESPATCH OF THE 2020 INTERIM REPORT;  
(II) DELAY IN PUBLICATION OF THE 2020 ANNUAL RESULTS  
AND  
(III) CONTINUED SUSPENSION OF TRADING**

This announcement is made by the board of directors (the “**Board**”) of China Tian Yuan Healthcare Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a) and 13.49(6) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated (i) 21 August 2020 in relation to suspension of trading in the shares of the Company; (ii) 31 August 2020 in relation to postponement of board meeting; (iii) 11 September 2020 in relation to resumption guidance, and the annual report of the Company for the year ended 31 December 2019; (iv) 30 September 2020 in relation to the delay in publication of the 2020 Interim Results and the despatch of the 2020 Interim Report; and (v) 15 December 2020 in relation to the further delay in publication of the 2020 Interim Results and despatch of the 2020 Interim Report.

Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined in the announcement dated 15 December 2020.

## **FURTHER DELAY IN PUBLICATION OF THE 2020 INTERIM RESULTS AND DESPATCH OF THE 2020 INTERIM REPORT**

The Board would like to inform the Shareholders and potential investors of the Company that the auditors of the Company require additional time to complete the review work of the subsidiaries due to the continuation of the impact of the outbreak of COVID-19 which has unexpectedly affected the review progress and was unable to publish the 2020 Interim Results as scheduled on 31 March 2021. The publication of the 2020 Interim Results is currently expected to take place in the week of 19 April 2021. Accordingly, the meeting of the Board for the purpose of, among other things, considering and approving the 2020 Interim Results will also be postponed until further notice by the way of announcements.

The Company will continue to use its best endeavours to publish the 2020 Interim Results and despatch the 2020 Interim Report to the Shareholders as soon as possible and will publish further announcement(s) to inform the Shareholders of any further updates on (i) the date(s) of the Board meeting to consider and approve the 2020 Interim Results and (ii) the despatch of the 2020 Interim Report as and when appropriate.

## **DELAY IN PUBLICATION OF THE 2020 ANNUAL RESULTS**

Pursuant to Rules 13.49(1) and 13.46(2)(a) of the Listing Rules, the Company is required to publish an announcement in respect of its results for the year ended 31 December 2020 (the “**2020 Annual Results**”) no later than 31 March 2021 and to despatch the annual report for the year ended 31 December 2020 (the “**2020 Annual Report**”) to the Shareholders on or before 30 April 2021.

The Board wishes to announce that the publication of the 2020 Annual Results will be delayed as the auditors of the Company requires additional time to complete the audit work of the subsidiaries and was unable to publish the 2020 Annual Results in accordance to the Listing Rules. The Board announces that, in light of the social distancing measures and travel restrictions imposed due to the continuation of the impact of the outbreak of COVID-19 which has unexpectedly affected the progress of our audit of the financial statements of the Group for the year ended 31 December 2020, additional time is required by the auditor of the Company to finalise the audit. The publication of the 2020 Annual Results is currently expected to take place in the week of 19 April 2021. Accordingly, the meeting of the Board for the purpose of, among other things, considering and approving the 2020 Annual Results will also be postponed until further notice by the way of announcements. The Board acknowledges that any delay in publishing the annual results will constitute non-compliance with Rule 13.49(1) of the Listing Rules. Notwithstanding this, the Board wishes to emphasise that the operation of the Group remains normal and that it will continue to work with the auditor of the Company closely with a view to publish the 2020 Annual Results as soon as possible.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and (2) of the Listing Rules, it must announce its results based on the financial results that have yet to be agreed with the Auditors. After due and careful consideration, the Board is of the view that it may not be appropriate for the Company to publish the unaudited management accounts of the Company for the 2020 Annual Results at this stage as it may not accurately reflect the financial performance and position of the Group.

The Company will publish further announcement(s) to inform the Shareholders of any further updates on (i) the expected date of publication of the 2020 Annual Results; (ii) the date(s) of the Board meeting to consider and approve the 2020 Annual Results; and (iii) the despatch of the 2020 Annual Report as and when appropriate.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended with effect from 9:00 a.m. on Monday, 24 August 2020 and will remain suspended until further notice.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**China Tian Yuan Healthcare Group Limited**  
**Zhang Xian**  
*Executive Director*

Hong Kong, 31 March 2021

*As at the date of this announcement, the Board is composed of seven directors of which Mr. Wang Huabing (chairman) and Ms. Zhang Xian are the executive directors, Ms. He Mei and Mr. Zhou Yuan are the non-executive directors and Mr. Hu Baihe, Mr. Yuen Kwok Kuen and Mr. Guo Jingbin are the independent non-executive directors.*